TOMI Environmental Solutions Inc (TOMZ) (Q2 2026) Earnings Call Highlights: Revenue Surges
TOMI Environmental Solutions (TOMZ) reported Q2 2026 revenue up 118% year over year, but a net loss of $382,000. Service revenue rose 3% YoY. Cash was $322,000. The company cited about $300,000 in merger-related transaction expenses tied to the Carbonium Core deal and said it expects $12 million revenue guidance for 2026 and breakeven by Q4.
How this was made
The 30-second read
Why it matters
Trading focus is likely on (1) whether the company can satisfy Nasdaq listing compliance and secure the $10M financing condition for the merger, (2) whether FDA 510(k) protocol/study work stays on schedule, and (3) whether revenue growth can reach the $12M 2026 guidance needed for breakeven by Q4.
Market read
This is a microcap earnings call where the most tradable elements are the reiterated 2026 revenue guidance and breakeven timing, contrasted with concrete near-term risks: low cash, elevated merger-related expenses, and an unsecured $10M financing condition plus uncertain FDA timeline.
What to watch
The $10M financing condition and uncertain FDA 510(k) timeline are gating items; any delay could push breakeven out despite cost-cutting and guidance language.
Background
The piece summarizes TOMI Environmental Solutions’ Q2 2026 earnings call, focusing on profitability, cash position, the Carbonium Core merger milestones, and regulatory progress for AgriMist and SteraMist.
Ticker impact
TOMI reported Q2 2026 net loss of $382,000, with $300,000 elevated merger-related expenses and low cash of $322,000.
Near-term downside bias on financing and FDA/merger timeline uncertainty; upside possible if investors focus on the reiterated 2026 revenue guidance and expected fee normalization post-merger.
The article provides concrete downside datapoints (net loss, low cash, elevated transaction fees, $10M financing condition not yet secured) plus conditional upside (prototype contracts in final stages, expected fee reduction, guidance to $12M and breakeven by Q4).
Market effects
Reinforces demand narratives for sterilization and decontamination technologies, but the key signal is execution risk around regulatory clearances and commercialization timelines.
No clear regional spillover beyond US-listed microcap sentiment.
Limited, as the disclosed catalysts are company-specific (FDA 510(k), EPA label commercialization, and a specific merger prototype).
Counterpoint
Investors may underweight the cash and loss figures because management reiterated a 2026 revenue path to cover operating expenses and expects professional fees to fall materially after the Carbonium Core deal closes.
Key entities
- companyTOMI Environmental Solutions Inc
NASDAQ-listed company reporting Q2 2026 results and providing updates on the Carbonium Core merger, AgriMist commercialization, and FDA 510(k) steps.
- transactionCarbonium Core merger
Merger subject to conditions including regaining Nasdaq compliance and raising $10 million for the combined companies.
- productAgriMist
EPA registration granted; management says it is not in the current pipeline figures and is expected to add as commercialization begins.
- regulatoryFDA 510(k) clearance
Next steps involve creating protocols, conducting studies, and reporting results; management expects another quarter for a more accurate timeline.
